Kodiak Sciences Inc.
KOD
Peringkat dalam Saham
#3086
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Harga Saham
$93.69
Kapitalisasi Pasar
$5.89B
Perubahan (1 hari)
2.56%
Perubahan (1 tahun)
429.32%
Negara
US
Perdagangan Kodiak Sciences Inc. (KOD)
Kategori
Healthcare
Riwayat pemecahan saham untuk Kodiak Sciences Inc. (KOD)
Saham Kodiak Sciences Inc. (simbol: KOD) telah mengalami total 1 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Feb 23, 2022.
Satu lembar saham KOD yang dibeli sebelum Feb 23, 2022 sekarang setara dengan 5 lembar saham KOD.
Pemecahan saham terbaru terjadi pada Feb 23, 2022.
Satu lembar saham KOD yang dibeli sebelum Feb 23, 2022 sekarang setara dengan 5 lembar saham KOD.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| 2022-02-23 | 5:1 | x5 | x5 |
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
